NCT06261905View on ClinicalTrials.gov

Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Opioid Use Disorder
Interventions
DRUG

[11C]-PHNO

PHNO is used as a tracer for in-vivo imaging.

DIETARY_SUPPLEMENT

Calcitriol

Calcitriol is an active form of Vitamin D and is given in 3 0.5mcg capsules per dose.

OTHER

Placebo Control

A placebo is an inert capsule, which contains no active ingredients. The placebo will be given in 3 0.5mcg capsules per dose.

PROCEDURE

PET Scan

A high resolution PET Scan performed using a NeurExplorer CT scanner.

Trial Locations (1)

06510

Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

Yale University

OTHER

NCT06261905 - Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System | Biotech Hunter | Biotech Hunter